TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6340552

Group type: EXPERIMENTAL
Intervention: Enprofylline 2 mg/kg b.wt.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enprofylline 4 mg/kg b.wt.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enprofylline (both doses)
Number of subjects: 24
Study: 31875000

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil based therapy
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: PRO-C3 (pro-peptide of type III collagen)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: C3M (degradation of type III collagen) and PRO-C3 ratio
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: PRO-C3 (adjusted for CA19-9 and clinical covariates)
Number of subjects: 176
Study: 29417793

Group type: EXPERIMENTAL
Intervention: Oral supplement (biotin, probiotic, vitamin E, zinc, nicotinamide; males: beta sitosterol and Boswellia serrata; females: myo‐inositol and folic acid) and topical cream device (verbascoside, Ocimum gratissimum, salicylic acid, gluconolactone, complex alpha‐hydroxy acids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical cream device (verbascoside, Ocimum gratissimum, salicylic acid, gluconolactone, complex alpha‐hydroxy acids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25856160

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (0.45 mg/day) with intermittent progesterone (200 mg/day for 12 days a month)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol (50 µg/day) with intermittent progesterone (200 mg/day for 12 days a month)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo pills and patch
Number of subjects: 117
Study: 25367551

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg + normal saline 0.05 ml/kg (DEX)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg/kg + normal saline 0.05 ml/kg (KET)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg/kg + dexmedetomidine 0.5 μg/kg (KETODEX)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo (volume-matched normal saline 0.15 mL/kg + normal saline 0.05 mL/kg)
Number of subjects: 400
Study: 22640724

Group type: EXPERIMENTAL
Intervention: Avoidance responses in a modified Stroop task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Approach responses in a modified Stroop task
Number of subjects: 0
Study: 20500877

Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol succinate
Number of subjects: 24

Group type: COMPARATOR
Intervention: 50 mg carvedilol
Number of subjects: 24
Study: 17980941

Group type: EXPERIMENTAL
Intervention: Experimental muscle pain
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control situation
Number of subjects: 20
Study: 15950631

Group type: EXPERIMENTAL
Intervention: Utrogest 200 (200 mg vaginal capsules, three times per day)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Crinone 8% (vaginal gel, two times per day)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Utrogest 200
Number of subjects: 430

Group type: COMPARATOR
Intervention: Crinone 8%
Number of subjects: 430
Study: 11474769

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AEDs) such as oxcarbazepine, levetiracetam, zonisamide, lamotrigine, and topiramate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine or topiramate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zonisamide and levetiracetam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zonisamide, lamotrigine, topiramate, and levetiracetam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AEDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of new AEDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First therapy given to newly diagnosed patients
Number of subjects: 0
Study: 9725503

Group type: EXPERIMENTAL
Intervention: Riluzole (Rilutek)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proc MIXED (SAS)
Number of subjects: 0
Study: 8306268

Group type: EXPERIMENTAL
Intervention: IMMU-4 99mTc-Fab' fragments (1 mg, 19.3 mCi average)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: IMMU-4 99mTc-Fab' fragments
Number of subjects: 35
Study: 2471472

Group type: EXPERIMENTAL
Intervention: Trimethoprim (200 mg with procainamide dose after 100 mg twice a day for 2 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 790550

Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg/day)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Indomethacin (100 mg/day)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Ketoprofen (200 mg/day)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Phenylbutazone (300 mg/day)
Number of subjects: 137
Study: 30501977

Group type: EXPERIMENTAL
Intervention: Motor Relearning Program
Number of subjects: 488

Group type: COMPARATOR
Intervention: Bobath Approach
Number of subjects: 488
Study: 28091641

Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: GnRH analog therapy with pomegranate extract
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 26586495

Group type: EXPERIMENTAL
Intervention: Low-to-moderate intensity exercise (LIG; n=44; 60-65% VO2peak, 50-65% 1RM)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Moderate-to-high intensity exercise (HIG; n=40; 75-80% VO2peak, 65-80% 1RM)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (n=75)
Number of subjects: 159
Study: 24585202

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg (add-on to metformin + sulfonylurea)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg (add-on to metformin + sulfonylurea)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 0
Study: 21829006

Group type: EXPERIMENTAL
Intervention: IM peribulbar injection
Number of subjects: 200

Group type: COMPARATOR
Intervention: IT peribulbar injection
Number of subjects: 200
Study: 20014598

Group type: EXPERIMENTAL
Intervention: Ropivacaine 19.5 mg with fentanyl 20 microg (group R)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Bupivacaine 13 mg with fentanyl 20 microg (group B)
Number of subjects: 52
Study: 17563982

Group type: EXPERIMENTAL
Intervention: Balneopelotherapy (sulfide mud)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Balneopelotherapy (sulfide mud) plus Transcranial Electro-stimulation (TCE)
Number of subjects: 60
Study: 15638236

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered as three infusions at 0, 2, and 6 weeks, then every 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methylprednisolone (0.7-1 mg/kg) daily for one week followed by tapering regimen
Number of subjects: 20
Study: 11442865

Group type: EXPERIMENTAL
Intervention: Caudal tramadol 2 mg.kg‐1 (group T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caudal morphine 0.03 mg.kg‐1 (group M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (group C) received morphine sulphate 0.03 mg.kg‐1 at the end of surgery, caudally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caudal morphine or tramadol (presurgical)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caudal morphine (postsurgical)
Number of subjects: 0
Study: 9007773

Group type: EXPERIMENTAL
Intervention: Isoinertial trunk extensor strength
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Isometric trunk extensor strength
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Torso length
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Functional testing
Number of subjects: 28
Study: 8496640

Group type: EXPERIMENTAL
Intervention: Mini‐Shah grommet
Number of subjects: 116

Group type: COMPARATOR
Intervention: Shah grommet
Number of subjects: 116
Study: 2896653

Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30019843

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon catheters (PEB)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 136
Study: 26835876

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 87
Study: 24102986

Group type: EXPERIMENTAL
Intervention: Rhythm control arm
Number of subjects: 693

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 693
Study: 22623385

Group type: COMPARATOR
Intervention: Control (C) group with untreated mushrooms providing 0.85 μg/d ergocalciferol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: M1 group with UV-treated mushrooms providing 8.8 μg/d ergocalciferol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: M2 group with UV-treated mushrooms providing 17.1 μg/d ergocalciferol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Supplement (S) group with purified ergocalciferol plus untreated mushrooms providing a total of 28.2 μg/d
Number of subjects: 38
Study: 20797476

Group type: EXPERIMENTAL
Intervention: Oily fish (salmon) diet
Number of subjects: 92

Group type: COMPARATOR
Intervention: Freshwater fish diet
Number of subjects: 92

Group type: COMPARATOR
Intervention: Pork/chicken/beef diet
Number of subjects: 92
Study: 18580877

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg in divided b.i.d. dose
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 16617380

Group type: EXPERIMENTAL
Intervention: Dexrazoxane (group D)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Anthracyclines only (group C)
Number of subjects: 158
Study: 14565629

Group type: EXPERIMENTAL
Intervention: New ultrasonic method for direct assessment of maximal varicose vein diameter (VVD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New ultrasonic method for detecting changes in VVD induced by pharmacologic treatment
Number of subjects: 0
Study: 11106838

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication (specifically diuretics)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Other antihypertensive drugs
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: High 2-h OGTT value (>9.0 mmol/l)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: High fasting insulin level (>12.0 mU/l)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: High triglyceride level (>/=1.3 mmol/l)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: High BMI (>/=28.0 kg/m(2))
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Hypertension (BP 160/95 or antihypertensive medication)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Normotensive subjects
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 2-h OGTT concentration
Number of subjects: 207
Study: 8797128

Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg (increased to 40 mg after 8 weeks, average 25.6 mg)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Enalapril 10 mg (increased to 20 mg after 8 weeks, average 12.9 mg)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 195

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 195
Study: 8427433

Group type: EXPERIMENTAL
Intervention: MPC (meperidine 2 mg/kg + promethazine 1 mg/kg + chlorpromazine)
Number of subjects: 87

Group type: COMPARATOR
Intervention: MP (meperidine 2 mg/kg + promethazine 1 mg/kg)
Number of subjects: 87
Study: 3592208

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg ketamine intravenously
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine intravenously
Number of subjects: 20
Study: 30343315

Group type: EXPERIMENTAL
Intervention: 32°C
Number of subjects: 150
Study: 26806397

Group type: COMPARATOR
Intervention: FOLFIRI (irinotecan with leucovorin/5-fluorouracil)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: FUPEP (PEP02 with leucovorin/5-fluorouracil)
Number of subjects: 55

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: FUPEP
Number of subjects: 55
Study: 25027018

Group type: EXPERIMENTAL
Intervention: AKI-recovery group
Number of subjects: 4315

Group type: COMPARATOR
Intervention: Non-AKI group
Number of subjects: 4315

Group type: EXPERIMENTAL
Intervention: AKI alone (without diabetes)
Number of subjects: 4315

Group type: COMPARATOR
Intervention: Diabetes alone (without AKI)
Number of subjects: 4315
Study: 22853642

Group type: EXPERIMENTAL
Intervention: Short bouts of structured physical activity (SBS‐PA) - 10 min structured PA routines, twice daily, followed by 20 min unstructured playtime
Number of subjects: 315

Group type: COMPARATOR
Intervention: Unstructured physical activity (UPA) - 30 min supervised unstructured free playtime, twice daily
Number of subjects: 315
Study: 19534290

Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (SEPs)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lumbar-recorded SEPs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sensory nerve stimulated SEPs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional electrophysiologic methods (needle EMG, late responses, nerve conduction studies)
Number of subjects: 20
Study: 16835746

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with autologous peripheral blood stem cell transplantation (ASCT)
Number of subjects: 35
Study: 15718881

Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control
Number of subjects: 93
Study: 12546253

Group type: EXPERIMENTAL
Intervention: Capitated Assertive Community Treatment (ACT) program
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 500
Study: 9506802

Group type: EXPERIMENTAL
Intervention: Caffeinated soft drink (CC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low Na+ mineral water (MW)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isotonic carbohydrate‐electrolyte solution (CES)
Number of subjects: 8
Study: 8568707

Group type: EXPERIMENTAL
Intervention: Focal laser therapy in Group I
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group in Group I
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Focal and scatter laser therapy in Group II
Number of subjects: 84
Study: 3219852

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 250 micrograms + ethinyl estradiol 50 micrograms (Neogynon)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 250 micrograms + ethinyl estradiol 30 micrograms (Eugynon 30)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 150 micrograms + ethinyl estradiol 30 micrograms (Microgynon)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Norethisterone acetate 1 mg + ethinyl estradiol 50 micrograms (Minovlar)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Control group (CuT220c IUD users)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: All OC users
Number of subjects: 407
Study: 31888365

Group type: EXPERIMENTAL
Intervention: Surgery (fracture fixation or humeral head replacement)
Number of subjects: 250
Study: 28802628

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Housework physical activity (HPA)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Gardening physical activity (GPA)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 420
Study: 27355261

Group type: EXPERIMENTAL
Intervention: Liberal fluid regimen (LIB) - crystalloid 12 mL/kg/h
Number of subjects: 330

Group type: COMPARATOR
Intervention: Restricted fluid regimen (RES) - crystalloid 6 mL/kg/h
Number of subjects: 330
Study: 25742370

Group type: EXPERIMENTAL
Intervention: Resistance Exercise via Negative Eccentric Work (RENEW)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard care control group (Active Control)
Number of subjects: 42
Study: 23506716

Group type: EXPERIMENTAL
Intervention: Standard laparoscopic supracervical hysterectomy (n = 70)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy with excision of the endocervix in a reverse cone pattern (n = 70)
Number of subjects: 140
Study: 21091245

Group type: EXPERIMENTAL
Intervention: Black soy peptide supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 19178101

Group type: EXPERIMENTAL
Intervention: Supervised toothbrushing (Test group A, n = 156)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Fluoride gel applications (Test group B, n = 118)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Control group (n = 137)
Number of subjects: 411
Study: 17078213

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Captopril (25 mg)
Number of subjects: 43
Study: 14599998

Group type: EXPERIMENTAL
Intervention: 5-year exercise-centered health-promoting programme
Number of subjects: 245

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 245
Study: 10911579

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 236

Group type: COMPARATOR
Intervention: Nonaspirin group
Number of subjects: 236
Study: 8615243

Group type: EXPERIMENTAL
Intervention: T2-weighted fast spin-echo imaging with fat suppression
Number of subjects: 177

Group type: COMPARATOR
Intervention: T2-weighted fast spin-echo imaging without fat suppression
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: T2-weighted fast spin-echo imaging with and without fat suppression
Number of subjects: 177
Study: 1632174

Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac 75 mg over 60 min, followed by an infusion of 5 mg/h for 15 h, then 50 mg every 8 h orally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion and dextropropoxyfen per os
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac infusion of 75 mg over 15 min (one or two bolus infusions)
Number of subjects: 20
Study: 6235099

Group type: EXPERIMENTAL
Intervention: Ortho Novum 1/35 (O/N)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ovcon 35 (OV)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nordette (N)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Levonorgestrel (1-Ng)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 1-Ng and ethinylestradiol combination
Number of subjects: 26
Study: 31675083

Group type: EXPERIMENTAL
Intervention: Incentive group (lottery-based incentive tied to daily self-weighing)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (weekly messages)
Number of subjects: 258
Study: 29716551

Group type: EXPERIMENTAL
Intervention: Participation in physical checkup examination
Number of subjects: 1463

Group type: COMPARATOR
Intervention: Non-participation in community activities
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: Health consciousness and smoking status
Number of subjects: 1463

Group type: EXPERIMENTAL
Intervention: IADL and physical functioning scores
Number of subjects: 1463
Study: 26558731

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24751780

Group type: EXPERIMENTAL
Intervention: Intervention sites
Number of subjects: 0
Study: 22215481

Group type: EXPERIMENTAL
Intervention: Weight Management System (remote daily weight monitoring, daily feedback, customized information, proprietary algorithm)
Number of subjects: 0
Study: 21629525

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18090280

Group type: EXPERIMENTAL
Intervention: Raltegravir (100 mg, 200 mg, 400 mg, or 600 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 0
Study: 15591732

Group type: EXPERIMENTAL
Intervention: Glass ionomer fissure sealant placed on primary molars (n=241)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo (control group, n=267)
Number of subjects: 508
Study: 12757221

Group type: EXPERIMENTAL
Intervention: Rapid dipstick assay for S. typhi-specific immunoglobulin M
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Combination of dipstick assay and culture
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Dipstick assay
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Culture
Number of subjects: 473
Study: 9927098

Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide and albuterol sulfate
Number of subjects: 357

Group type: COMPARATOR
Intervention: Albuterol base alone (control)
Number of subjects: 357
Study: 7485698

Group type: EXPERIMENTAL
Intervention: Ro 46‐2717 (CS protein) and Ro 46‐2924 (MSA‐2) vaccines at low (20 micrograms) and high (100 micrograms) doses
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (alum alone)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ro 46‐2717 and Ro 46‐2924 vaccines (after third immunization)
Number of subjects: 33
Study: 1967720

Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U over 5 min)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Streptokinase (1.5 MU over 1 h)
Number of subjects: 128
Study: 7388852

Group type: EXPERIMENTAL
Intervention: Combined treatment with lignocaine, procainamide, and practolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 6

Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 6
Study: 31613055

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs) therapy (2 intravenous doses of 2×10^8 cells every 3 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (MSCs and placebo)
Number of subjects: 20
Study: 31415378

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose, 1 μg/kg for 10 minutes and continuous infusion, 0.4 μg/kg/hr)
Number of subjects: 126